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Abstract
Introduction:  Sorafenib  chemotherapy  is  the  ﬁrst-line  therapy  for  patients  with  hepatocellular
carcinoma  (HCC)  in  an  advanced  stage.  The  aim  of  this  study  was  to  evaluate  prognostic  factors
of survival  in  HCC  patients  treated  with  sorafenib,  in  real-life  clinical  practice.
Material  and  methods:  Retrospective  study  of  HCC  patients  who  initiated  treatment  with
sorafenib, following  assessment  and  indication  from  the  multidisciplinary  group.
Results:  There  were  included  36  patients,  mostly  male  (89%)  and  with  a  mean  age  of  65  years.
The main  etiologies  were  chronic  hepatitis  C  (44%)  and  alcoholic  liver  disease  (36%).  Twenty
patients  (56%)  were  classiﬁed  as  Child--Pugh  A  and  16  patients  (44%)  as  Child--Pugh  B.  Half  of
the patients  group  were  staged  as  BCLC  C  and  the  remaining  as  BCLC  B.  Signiﬁcant  adverse
events were  observed  in  15  patients  (42%)  and  were  associated  with  longer  survival  (21.5  vs.
3.2 months,  p  <  0.001).  The  most  frequent  adverse  events  were  diarrhea  and  palmar-plantar
syndrome.  Median  survival  was  17.3  months  for  Child--Pugh  A  versus  3.2  months  for  Child--Pugh
B patients  (p  =  0.001).  Within  Child--Pugh  A,  median  OS  was  21.5  months  for  BCLC  B  patients
and 15.7  months  for  BCLC  C  patients  (p  =  0.001).
Discussion  and  conclusions: The  main  prognostic  factors  beyond  Child--Pugh  class  and  BCLC
stage included  the  occurrence  of  signiﬁcant  adverse  events.  Being  related  to  increased  time
of exposure  to  the  drug,  it  points  out  the  need  of  dose  reducing  instead  of  discontinuation
whenever  signiﬁcant  adverse  events  occur.
© 2016  Sociedade  Portuguesa  de  Gastrenterologia.  Published  by  Elsevier  Espan˜a,  S.L.U.  This  is
r  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/an open  access  article  unde
by-nc-nd/4.0/).∗ Corresponding author.
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Tratamento  de  Carcinoma  Hepatocelular  Com  Sorafenib:  Avaliac¸ão  de  Fatores  de
Prognóstico  e  um  Indício  Prático  para  a  Orientac¸ão  dos  Doentes
Resumo
Introduc¸ão:  O  tratamento  de  primeira  linha  de  doentes  com  carcinoma  hepatocelular  (HCC)
em estadio  avanc¸ado  é  a  quimioterapia  com  sorafenib.  O  objetivo  deste  estudo  foi  avaliar  os
fatores de  prognóstico  de  sobrevivência  em  doentes  com  HCC  tratados  com  sorafenib,  na  prática
clínica.
Material e  métodos:  Estudo  retrospetivo  com  inclusão  dos  doentes  com  HCC  que  iniciaram
tratamento  com  sorafenib,  após  avaliac¸ão  e  decisão  de  grupo  em  reunião  multidisciplinar.
Resultados:  Foram  incluídos  36  doentes,  que  eram  em  maioria  do  género  masculino  (89%)  e
com idade  média  de  65  anos.  As  principais  etiologias  eram  a  hepatite  C  crónica  (44%)  e  a
doenc¸a hepática  alcoólica  (36%).  Vinte  doentes  (56%)  foram  classiﬁcados  como  Child-Pugh  A  e
16 doentes  (44%)  como  Child-Pugh  B.  A  amostra  apresentava  em  metade  dos  casos  estadio  BCLC
C e  os  restantes  BCLC  B.  Quinze  doentes  (42%)  desenvolveram  efeitos  adversos  signiﬁcativos,
que se  associaram  com  maior  sobrevivência  (21,5  vs  3,2  meses,  p  <  0,001).  Os  efeitos  adversos
mais frequentes  foram  diarreia  e  síndrome  palmo-plantar.  A  sobrevivência  global  mediana  foi  de
6,8 meses  (IC  95%,  3-10,6).  A  sobrevivência  mediana  foi  de  17,3  meses  nos  doentes  Child-Pugh
A versus  3,2  meses  nos  casos  Child-Pugh  B  (p  =  0,001).  Considerando  os  doentes  Child-Pugh  A,
a sobrevivência  mediana  foi  de  21,5  meses  para  o  estadio  BCLC  B  e  15,7  meses  para  o  estadio
BCLC C  (p  =  0,001)
Discussão  e  conclusões: Os  principais  fatores  prognósticos,  além  da  classiﬁcac¸ão  de  Child-Pugh
e do  estadiamento  BCLC,  incluíram  a  ocorrência  de  efeitos  adversos.  Estes,  relacionados  com
o tempo  de  exposic¸ão  ao  fármaco,  assinalam  a  importância  de  uma  estratégia  de  reduc¸ão  de
dose em  vez  de  descontinuac¸ão  quando  se  manifestam  efeitos  adversos  signiﬁcativos.
© 2016  Sociedade  Portuguesa  de  Gastrenterologia.  Publicado  por  Elsevier  Espan˜a,  S.L.U.  Este
e´ um  artigo  Open  Access  sob  uma  licenc¸a  CC  BY-NC-ND  (http://creativecommons.org/licenses/
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. Introduction
epatocellular  carcinoma  (HCC)  is  a  signiﬁcant  health
roblem.  Globally  is  the  second  most  common  cause
f  cancer-associated  death  and  the  ﬁfth  most  frequent
eoplasm.1 The  main  risk  factors  for  the  onset  of  HCC
re  well  recognized,  including  the  presence  of  cirrhosis,
hronic  hepatitis  C  and  hepatitis  B  infections  and  heavy
lcohol  consumption.2 In  an  early  stage  disease,  there  are
otentially  curative  therapies,  such  as  surgical  resection,
ransplantation  and  locoregional  procedures.3 However,  at
he  time  of  diagnosis,  a  large  number  of  patients  present  an
dvanced  stage  disease,  according  to  the  Barcelona  Clinic
iver  Cancer  (BCLC)  classiﬁcation.4
Until  the  advent  of  sorafenib,  effective  therapies
or  patients  diagnosed  at  an  advanced  stage,  or  that
rogressed  after  other  treatments,  were  very  limited.2 Sys-
emic  chemotherapy  and  tamoxifen  are  not  recommended.5
orafenib  is  a  multikinase  inhibitor  with  activity  against
umerous  kinases  such  as  VEGFR2,  PDGFR,  FGFR1,  Raf-
,  B-Raf  and  c-Kit  receptors.6 Its  antiproliferative  and
ntiangiogenic  activity  causes  a  delay  in  tumor  progres-
ion  and  may  induce  tumor  regression.7 Sorafenib  was
he  ﬁrst  agent  that  signiﬁcantly  improved  the  survival  of
atients  with  an  advanced  stage  of  HCC  and  it  is  currently
he  only  approved  systemic  therapy  for  this  disease.  Its
pproval  was  based  on  the  efﬁcacy  and  the  safety  results
eported  by  two  multicenter,  randomized,  double-blind,
lacebo-controlled  trials.8 The  Sorafenib  HCC  Assessment
andomized  Protocol  (SHARP)9 and  the  Asia-Paciﬁc10 trials
2
n
aemonstrated  a  signiﬁcantly  prolonged  median  overall  sur-
ival  (OS)  of  10.7  and  6.5  months,  respectively,  compared
ith  7.9  and  4.2  months  for  those  receiving  placebo,  respec-
ively.  The  large  majority  of  patients  enrolled  in  these
wo  studies  were  classiﬁed  as  Child--Pugh  A  and  BCLC
.  The  safety  proﬁle  and  efﬁciency  of  treatment  with
orafenib  in  ﬁeld  practice  has  been  evaluated  by  sev-
ral  studies,  including  the  SOFIA  study11 and  the  GIDEON
tudy.12 The  most  frequent  sorafenib-related  adverse  events
eported  were  fatigue,  diarrhea  and  palmar-plantar  ery-
hrodysesthesia  syndrome.11 In  a  prospective  cohort  in
pain,  17%  of  HCC  patients  were  treated  with  sorafenib,
ince  it  become  available.13 Despite  the  existence  of  numer-
us  studies  on  the  efﬁcacy  of  sorafenib,  there  is  still  a
ack  of  information  on  predictive  factors  of  response  to
orafenib.8
The  aim  of  this  study  was  to  evaluate  the  prognostic  fac-
ors  of  survival  in  HCC  patients  with  advanced  BCLC  stage,
r  intermediate  stage  as  second  line,  treated  with  sorafenib
n  real-life  practice  conditions.
. Methods
etrospective  study  of  HCC  patients  who  initiated  treatment
ith  sorafenib  since  2010,  with  a  follow  up  period  up  to
014.
The  diagnosis  of  HCC  was  established  according  to  inter-
ational  guidelines,  namely  the  AASLD  criteria14 until  2012
nd  the  EASL-EORTC  guidelines5 since  2012.
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Table  1  Patients  baseline  characteristics.
Variable  n  =  36
Age  (years)  --  mean  ±  SD  65.2  ±  11.7
Gender --  n  (%)
Male  32  (89)
Female  4  (11)
Etiology  --  n  (%)
HVC  infection  16  (44)
Alcohol  consumption  13  (36)
HVB infection  3  (8)
HVC/HVB  co-infection  1  (3)
Hemochromatosis  1  (3)
NASH 1  (3)
Cryptogenic  1  (3)
ECOG PS  --  n  (%)
0  28  (79)
1 8  (22)
Child--Pugh  class  --  n  (%)
A 20  (56)
B 16  (44)
BCLC stage  --  n  (%)
B 18  (50)
C 18  (50)
Previous  therapy  --  n  (%)
None  22  (61)
Liver resection  4  (11)
TACE 5  (14)
RFA 2  (6)
Liver resection  and  TACE  2  (6)
RFA and  TACE  1  (3)
Metastasis  --  n  (%)
No 25  (69)
Yes 11  (31)
Tumor Size  (cm)  --  mean  ±  SD  7.9  ±  4.4
AFP  (mg/mL)  --  median  (P25;  P75)  280  (28;  2956)
Albumina (g/L)  --  mean  ±  SD  33.5  ±  5.3
Plateletb (109/L)  --  median  (P25;  P75)  145  (83;  247)
Total Bilirubina (mg/dL)  --  median
(P25;  P75)
2.1  (1.2;  2.8)
AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer;
ECOG PS, Eastern Cooperative Oncology Group Performance
Status; HVB, hepatitis B virus; HVC, hepatitis C virus; NASH, non-
alcoholic steatohepatitis; P, percentile; RFA, radiofrequency
ablation; SD, standard deviation; TACE, transarterial chemoem-
bolization.
a n = 34.
3
S
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Sorafenib  was  given  as  ﬁrst  line  therapy  in  advanced
stage  or  as  second  line  in  intermediate  stage  patients  after
locoregional  treatment,  following  assessment  and  indication
from  the  multidisciplinary  group  special  dedicated  to  this
topic.  Therapy  regime  was  400  mg  of  sorafenib  twice  daily,
except  for  those  who  reduced  the  dose  to  400  mg  daily  due
to  adverse  events.
At  baseline,  clinical  and  analytical  variables  were
assessed.  During  sorafenib  treatment,  the  occurrence  of
adverse  events,  dose  reduction  or  suspension,  serum  AFP
levels  and  imagiological  response  were  evaluated.  Data  was
collected  from  clinical  records  of  patients.
Adverse  events  were  evaluated  according  to  the  National
Institute  Common  Terminology  Criteria  for  Adverse  Events
v4.03.  Signiﬁcant  adverse  events  were  deﬁned  as  grade  2  or
higher.
OS  was  measured  from  the  starting  date  of  sorafenib
therapy  until  the  date  of  the  last  contact.  Tumor  response
was  accessed  by  computed  tomography  (CT)  or  magnetic
resonance  imaging  (MRI)  according  to  Response  Evaluation
Criteria  In  Solid  Tumors  (RECIST)  and  modiﬁed  RECIST  (mRE-
CIST).
The  primary  endpoint  of  the  study  was  identiﬁcation  of
predictive  factors  of  prognosis.  The  secondary  endpoint  was
evaluation  of  safety.
This  study  was  approved  by  the  ethics  committee  of  this
center.  All  data  were  analyzed  by  descriptive  statistics  and
Fisher’s  exact  test  for  categorical  variables.  Survival  data
was  analyzed  by  Kaplan--Meier  statistics  with  the  Log-rank
test.  Statistical  signiﬁcance  was  established  at  p  <  0.05  for
all  tests.  All  statistical  analysis  was  performed  by  use  of  IBM®
SPSS® Statistics  v21.
3. Results
3.1.  Patients
During  the  study  period,  36  consecutive  patients  from  the
gastroenterology  department  were  included,  corresponding
to  13%  of  the  patients  evaluated  by  the  multidisciplinary
group.  The  main  characteristics  of  the  patients  are  reported
in  Table  1.  The  majority  of  patients  were  male  (89%)  and
the  mean  age  was  65  years.  A  histological  diagnosis  of  hepa-
tocellular  carcinoma  was  performed  in  28%  of  the  patients.
Regarding  the  cancer  etiology,  the  main  causes  were  chronic
HVC  infection  in  16  patients  and  heavy  alcohol  consumption
in  13  patients.
According  to  Child--Pugh  score  of  chronic  liver  disease,
20  patients  were  classiﬁed  as  Child--Pugh  A  and  16  patients
as  Child--Pugh  B.  According  to  BCLC  staging  classiﬁcation,
half  of  the  patients  were  BCLC  C  and  the  remaining  BCLC  B.
Twenty-two  patients  (61%)  received  sorafenib  as  ini-
tial  treatment.  Transarterial  chemoembolization  (TACE)  and
liver  resection  were  the  most  common  previous  treatment
before  sorafenib.  Four  patients  performed  other  treatment
besides  sorafenib,  particularly,  three  patients  underwent
TACE  and  one  patient  had  radiofrequency  ablation  (RFA).The  median  treatment  duration  was  4.3  months  (P25:
1.7;  P75:  19.9),  and  treatment  duration  was  longer  in
Child--Pugh  A  versus  Child--Pugh  B  patients  (p  =  0.001)  and
in  BCLC  B  versus  BCLC  C  patients  (p  =  0.031).
a
P
p
sb n = 35.
.2.  Safety
igniﬁcant  adverse  events  with  sorafenib  were  observed
n  15  patients  (42%).  The  most  frequent  were  diarrhea
nd  palmar-plantar  erythrodysesthesia  syndrome  (Table  2).
articularly,  nine  patients  (25%)  had  diarrhea  and  seven
atients  (20%)  exhibited  palmar-plantar  erythrodysesthesia
yndrome  that  was  improved  in  most  cases  with  sorafenib
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Table  2  Drug-related  signiﬁcant  adverse  events.
Signiﬁcant  adverse  events  n  =  36  (%)
None  21  (58)
One 12  (33)
Diarrhea  7  (19)
Palmar-plantar  erythrodysesthesia  syndrome  4  (11)
Ischemic  cerebrovascular  disease  1  (3)
Two 3  (8)
Diarrhea  and  palmar-plantar
erythrodysesthesia  syndrome
2  (7)
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(95%  1.8--6.6)  (p  =  0.003).  There  was  no  statistically  signif-
icant  difference  in  OS  based  on  serum  AFP  levels,  platelet
count  and  age  variables.
Table  3  Median  survival  of  Child--Pugh  and  BCLC  classiﬁ-
cation paired  (p  =  0.001).
Patients  classiﬁcation  Median  survival  --
months  (95%  CI)
Child--Pugh  A  and  BCLC  B  21.5  (12.2--30.7)
Child--Pugh  A  and  BCLC  C  15.7  (3.3--28.2)Palmar-plantar  erythrodysesthesia  syndrome
and  myocardial  infarction
1  (3)
ose  reduction  and  medical  treatment.  Three  patients  pre-
ented  more  than  one  signiﬁcant  adverse  event.  In  the
otal  of  patients  with  adverse  events,  87%  were  classiﬁed
s  Child--Pugh  A  and  13%  as  Child--Pugh  B  (p  =  0.002)  and
7%  had  BCLC  B  and  33%  BCLC  C  stage  disease  (p  =  0.176).
ose  reduction  as  a  result  of  adverse  events  was  observed
n  13  patients  (36%).  Twenty-six  patients  (72%)  discontinued
orafenib  due  to  disease  progression  and  one  patient  due  to
ersistent  adverse  events,  namely  diarrhea.
.3.  Radiologic  response
alf  of  the  patients  performed  an  imaging  reevaluation,
ostly  by  abdominal  CT  or  MRI.  In  the  other  patients  the
ain  reasons  for  absence  of  radiologic  reassessment  were
hort  survival  (25%  of  patients  died  in  the  ﬁrst  3  months)
nd  clinical  progression.
These  patients  were  evaluated  according  to  RECIST  crite-
ia,  two  patients  (6%)  had  partial  response,  nine  patients
25%)  were  classiﬁed  as  stable  disease  and  seven  patients
19%)  underwent  disease  progression.  Sixteen  patients  were
lso  evaluated  according  to  mRECIST  criteria,  one  patient
eached  complete  response,  four  patients  (11%)  had  partial
esponse,  three  patients  (8%)  had  stable  disease  and  eight
atients  (22%)  underwent  disease  progression.  Four  patients
ut  of  16  were  reclassiﬁed  into  a  different  response  stage
hen  applied  mRECIST  criteria.
.4.  Survival
t  the  time  of  analysis,  ﬁve  patients  were  still  alive  and  con-
inued  treatment  and  31  patients  have  died.  Median  OS  was
.8  months  (95%  CI,  3--10.6).  Survival  rates  differed  accord-
ng  to  the  Child--Pugh  class  (median  OS  Child--Pugh  A  17.3
onths  (95%  CI,  5.3--29.4)  versus  Child--Pugh  B  3.2  months
95%  CI,  0.9--5.5);  p  =  0.001)  (Fig.  1)  and  BCLC  stage  (mean
urvival  BCLC  B  was  21.5  months  (95%  CI,  7.5--35.4)  ver-
us  BCLC  C  4.2  months  (95%  CI,  1.7--6.7);  p  =  0.017).  When
e  paired  the  Child--Pugh  and  BCLC  scores,  greater  OS  was
bserved  in  patients  with  Child--Pugh  A  and  BCLC  B  (21.5
onths)  and  in  Child--Pugh  A  and  BCLC  C  (15.7  months)p  = 0.001)  (Table  3).
Patients  who  had  signiﬁcant  adverse  events  showed  a
igher  median  survival  (21.5  months,  95%  CI  14--29)  than
hose  without  signiﬁcant  adverse  events  (3.2  months,  95%igure  1  Kaplan--Meier  analysis  of  survival  of  Child--Pugh  A
nd Child--Pugh  B  patients  (p  =  0.001).
I  1.6--4.8)  (p  < 0.001)  (Fig.  2).  When  evaluating  the  survival
ith  the  stratiﬁcation  of  baseline  staging  (Child  A  patients
ith  BCLC  stage  B  or  C)  there  was  also  a  better  outcome  for
he  patients  that  experienced  adverse  events,  although  it
as  only  achieved  statistical  signiﬁcance  for  BCLC  C  patients
median  OS  15.7  months  with  adverse  events  vs.  4.6  months
ithout;  p  =  0.031)  and  not  for  BCLC  B  (median  OS  27  months
ith  adverse  events  vs.  4.4  months  without;  p  =  0.627).
The  survival  rate  of  the  group  of  patients  who  pre-
ented,  at  baseline,  total  bilirubin  levels  below  2  mg/dL
as  16.1  months  (95%  CI,  6.4--25.9)  versus  3.3  months  (95%
I,  1.3--5.3)  for  the  group  with  total  bilirubin  levels  above
 mg/dL  (p  =  0.004).  For  the  group  of  patients  who  had,  at
aseline,  serum  albumin  levels  above  35  g/L,  survival  rate
as  21.5  months  (95%  CI,  12.1--30.9)  and  for  the  group  who
resented  serum  albumin  levels  below  35  g/L  was  4.2  monthsChild--Pugh  B  and  BCLC  B  3.3  (0.2--6.3)
Child--Pugh  B  and  BCLC  C  3.2  (1.2--5.2)
BCLC, Barcelona Clinic Liver Cancer; CI, conﬁdence interval.
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dFigure  2  Kaplan--Meier  analysis  of  survival  of  patients  who
experienced  or  not  signiﬁcant  adverse  events  (p  <  0.001).
4. Discussion
This  study  conﬁrms  the  beneﬁt  of  sorafenib  in  OS,  namely  in
Child--Pugh  A  patients.  According  to  the  Child--Pugh  class,
Child--Pugh  A  patients  had  a  signiﬁcantly  higher  median
survival  versus  Child--Pugh  B,  as  veriﬁed  in  Pressiani  and
colleagues  study.15 Therefore,  liver  function  of  patients
in  sorafenib  therapy  is  an  important  prognostic  factor  of
survival.  We  also  found  signiﬁcant  differences  in  survival
for  the  group  of  patients  who  present  total  bilirubin  lev-
els  below  2  mg/dL  and  serum  albumin  levels  above  35  g/L.
These  measures  are  employed  in  the  criteria  of  Child--Pugh
classiﬁcation,  so  these  results  reﬂect  that  patients  with  bet-
ter  liver  function  (Child--Pugh  A)  have  a  greater  beneﬁt  of
sorafenib.
Concerning  OS,  our  results  were  not  inferior  to  the  Asia-
Paciﬁc  study,10 who  stated  a  median  OS  of  6.5  months  for
Child--Pugh  A  and  BCLC  C  patients.  In  our  study,  we  included
some  early  Child--Pugh  B  (7--8  points)  patients  that  were
expected  to  recover  to  Child--Pugh  A.  These  patients  out-
comes  with  reduced  beneﬁt  of  sorafenib  make  us  suggest
that  sorafenib  use  in  this  Child--Pugh  class  should  only  be
applied  in  clinical  trials.  Patients  with  BCLC  B  stage  had
a  higher  median  survival  than  BCLC  C.  These  results  are
consistent  with  SOFIA  study.11
The  authors  consider  sorafenib  a  safe  therapy  modal-
ity.  In  contrast  with  the  main  clinical  practice  studies,11,12
more  than  half  of  patients  receiving  sorafenib  experienced
no  adverse  events.  This  can  be  explained  by  the  fact  that  we
not  included  fatigue  as  a  signiﬁcant  adverse  event.  The  main
signiﬁcant  adverse  events,  such  as  diarrhea  and  palmar-
plantar  erythrodysesthesia  syndrome,  were  consistent  with
a
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hose  observed  in  others  studies.10--12 Regarding  signiﬁcant
dverse  events,  there  was  no  difference  between  BCLC  B  and
 stages,  however,  their  occurrence  was  signiﬁcantly  higher
n  Child--Pugh  A  patients  when  compared  with  Child--Pugh  B
atients,  different  from  previously  published  studies,12,15,16
hat  could  be  related  with  the  shorter  OS  of  Child  B
atients.  Thirteen  patients  (36%)  reduced  their  dose  due
o  adverse  events,  similarly  to  Asia-Paciﬁc  trial.10 Patients
ho  had  signiﬁcant  adverse  events  showed  a  higher  median
urvival.  Although  this  might  be  due  to  a  longer  treatment
xposure,  we  decided  to  reduce  the  dose  rather  than  dis-
ontinue  sorafenib.  It  is  also  important  to  mention  that
orafenib  suspension  was  mainly  due  to  disease  progres-
ion  with  liver  dysfunction,  than  due  to  adverse  events,
hich  occurred  in  only  one  patient.  In  a  similar  study  in
apan  the  authors  reported  that  skin  toxicity  related  to
orafenib  therapy  was  a  signiﬁcant  predictor  for  longer  sur-
ival,  although  it  led  to  treatment  discontinuation  in  11%  of
he  patients.17 An  European  study  also  addressed  this  issue
nd  identiﬁed  dermatologic  adverse  events,  requiring  dose
djustment  within  the  ﬁrst  60  days,  as  an  independent  pre-
ictor  off  better  outcome.  Nevertheless,  in  this  study  there
as  a  high  discontinuation  rate  due  to  drug  related  adverse
vents  (36%).18
In  Edeline  et  al  study,19 mRECIST  was  considered  to  be  a
seful  prognostic  parameter  that  might  be  helpful  to  guide
he  maintenance  of  sorafenib.  In  our  study,  fewer  patients
nderwent  evaluation  according  to  mRECIST,  mainly  due  to
hort  survival  and  clinical  progression,  not  allowing  us  to
ssume  conclusions  regarding  its  role  as  a  prognostic  param-
ter.
Personeni  and  colleagues  suggested  that  AFP  is  an  inde-
endent  variable  to  predictive  the  response  of  patients  with
epatocellular  carcinoma  doing  sorafenib,  but  it  should  be
ombined  with  the  evaluation  of  radiological  response.20
ur  study  did  not  ﬁnd  any  correlation  between  serum  AFP
evels  and  OS.  Furthers  studies  are  needed  to  validate  this
otentially  prognostic  factor.
Currently,  new  molecular  agents  for  second-line  treat-
ent  or  in  combination  with  sorafenib  are  under
nvestigation.21 Although  several  trials  were  negative  it  is
xpected  that  some  agents  could  further  improve  the  out-
ome  of  HCC  patients.
.  Conclusions
he  main  factor  of  prognosis  identiﬁed  beyond  Child--Pugh
lass  and  BCLC  stage,  as  previously  described,  was  the
ccurrence  of  signiﬁcant  adverse  events.  This  fact  could  be
elated  to  increased  time  of  exposure  to  the  drug,  depending
n  the  strategy  of  not  discontinuing  sorafenib,  but  reducing
ts  dose  instead.
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